1,432 Shares in Stryker Corporation $SYK Acquired by AXQ Capital LP

AXQ Capital LP acquired a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,432 shares of the medical technology company’s stock, valued at approximately $567,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Nuveen LLC bought a new stake in Stryker in the 1st quarter worth about $558,075,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Stryker by 66.7% during the 1st quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after acquiring an additional 549,643 shares during the last quarter. ABN AMRO Bank N.V. bought a new stake in shares of Stryker in the second quarter worth approximately $191,047,000. Finally, Vanguard Group Inc. raised its holdings in shares of Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after purchasing an additional 440,607 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 522,618 shares of company stock worth $185,577,237. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on SYK. Barclays lifted their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Truist Financial lifted their price objective on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a report on Friday, November 14th. BTIG Research restated a “buy” rating and set a $410.00 price target on shares of Stryker in a research note on Friday, November 14th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 price target on shares of Stryker in a research report on Friday, November 14th. Finally, Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Thirteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Stock Up 2.2%

Shares of SYK opened at $368.35 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market capitalization of $140.87 billion, a price-to-earnings ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The business’s 50 day simple moving average is $369.38 and its 200-day simple moving average is $380.70.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the business posted $2.87 earnings per share. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.